FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1841011077> ?p ?o ?g. }

• W1841011077 endingPage "378" @default.
• W1841011077 startingPage "368" @default.
• W1841011077 abstract "Immunotherapy is an ideal treatment modality to specifically target the diffusely infiltrative tumor cells of malignant gliomas while sparing the normal brain parenchyma. However, progress in the development of these therapies for glioblastoma has been slow due to the lack of immunogenic antigen targets that are expressed uniformly and selectively by gliomas.We utilized human glioblastoma cell cultures to induce expression of New York-esophageal squamous cell carcinoma (NY-ESO-1) following in vitro treatment with the demethylating agent decitabine. We then investigated the phenotype of lymphocytes specific for NY-ESO-1 using flow cytometry analysis and cytotoxicity against cells treated with decitabine using the xCelligence real-time cytotoxicity assay. Finally, we examined the in vivo application of this immune therapy using an intracranially implanted xenograft model for in situ T cell trafficking, survival, and tissue studies.Our studies showed that treatment of intracranial glioma-bearing mice with decitabine reliably and consistently induced the expression of an immunogenic tumor-rejection antigen, NY-ESO-1, specifically in glioma cells and not in normal brain tissue. The upregulation of NY-ESO-1 by intracranial gliomas was associated with the migration of adoptively transferred NY-ESO-1-specific lymphocytes along white matter tracts to these tumors in the brain. Similarly, NY-ESO-1-specific adoptive T cell therapy demonstrated antitumor activity after decitabine treatment and conferred a highly significant survival benefit to mice bearing established intracranial human glioma xenografts. Transfer of NY-ESO-1-specific T cells systemically was superior to intracranial administration and resulted in significantly extended and long-term survival of animals.These results reveal an innovative, clinically feasible strategy for the treatment of glioblastoma." @default.
• W1841011077 created "2016-06-24" @default.
• W1841011077 creator A5010449744 @default.
• W1841011077 creator A5015815617 @default.
• W1841011077 creator A5016190247 @default.
• W1841011077 creator A5017781109 @default.
• W1841011077 creator A5019281368 @default.
• W1841011077 creator A5025832921 @default.
• W1841011077 creator A5031810848 @default.
• W1841011077 creator A5043863125 @default.
• W1841011077 creator A5059056118 @default.
• W1841011077 creator A5071481657 @default.
• W1841011077 creator A5074942308 @default.
• W1841011077 creator A5078400193 @default.
• W1841011077 date "2015-09-01" @default.
• W1841011077 modified "2023-09-27" @default.
• W1841011077 title "Efficacy of systemic adoptive transfer immunotherapy targeting NY-ESO-1 for glioblastoma" @default.
• W1841011077 cites W1541816872 @default.
• W1841011077 cites W1817287223 @default.
• W1841011077 cites W1972173313 @default.
• W1841011077 cites W2009001195 @default.
• W1841011077 cites W2021988159 @default.
• W1841011077 cites W2028884054 @default.
• W1841011077 cites W2029286945 @default.
• W1841011077 cites W2052587346 @default.
• W1841011077 cites W2066031247 @default.
• W1841011077 cites W2069166009 @default.
• W1841011077 cites W2070748533 @default.
• W1841011077 cites W2094652659 @default.
• W1841011077 cites W2118982164 @default.
• W1841011077 cites W2121836743 @default.
• W1841011077 cites W2127734125 @default.
• W1841011077 cites W2131020006 @default.
• W1841011077 cites W2133499518 @default.
• W1841011077 cites W2146310224 @default.
• W1841011077 cites W2148401772 @default.
• W1841011077 cites W2153712501 @default.
• W1841011077 cites W2162630386 @default.
• W1841011077 cites W2560367415 @default.
• W1841011077 doi "https://doi.org/10.1093/neuonc/nov153" @default.
• W1841011077 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4767237" @default.
• W1841011077 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26330563" @default.
• W1841011077 hasPublicationYear "2015" @default.
• W1841011077 type Work @default.
• W1841011077 sameAs 1841011077 @default.
• W1841011077 citedByCount "32" @default.
• W1841011077 countsByYear W18410110772016 @default.
• W1841011077 countsByYear W18410110772017 @default.
• W1841011077 countsByYear W18410110772018 @default.
• W1841011077 countsByYear W18410110772019 @default.
• W1841011077 countsByYear W18410110772020 @default.
• W1841011077 countsByYear W18410110772021 @default.
• W1841011077 countsByYear W18410110772022 @default.
• W1841011077 countsByYear W18410110772023 @default.
• W1841011077 crossrefType "journal-article" @default.
• W1841011077 hasAuthorship W1841011077A5010449744 @default.
• W1841011077 hasAuthorship W1841011077A5015815617 @default.
• W1841011077 hasAuthorship W1841011077A5016190247 @default.
• W1841011077 hasAuthorship W1841011077A5017781109 @default.
• W1841011077 hasAuthorship W1841011077A5019281368 @default.
• W1841011077 hasAuthorship W1841011077A5025832921 @default.
• W1841011077 hasAuthorship W1841011077A5031810848 @default.
• W1841011077 hasAuthorship W1841011077A5043863125 @default.
• W1841011077 hasAuthorship W1841011077A5059056118 @default.
• W1841011077 hasAuthorship W1841011077A5071481657 @default.
• W1841011077 hasAuthorship W1841011077A5074942308 @default.
• W1841011077 hasAuthorship W1841011077A5078400193 @default.
• W1841011077 hasBestOaLocation W18410110771 @default.
• W1841011077 hasConcept C104317684 @default.
• W1841011077 hasConcept C142724271 @default.
• W1841011077 hasConcept C147483822 @default.
• W1841011077 hasConcept C150194340 @default.
• W1841011077 hasConcept C154317977 @default.
• W1841011077 hasConcept C167672396 @default.
• W1841011077 hasConcept C190727270 @default.
• W1841011077 hasConcept C202751555 @default.
• W1841011077 hasConcept C203014093 @default.
• W1841011077 hasConcept C2776090121 @default.
• W1841011077 hasConcept C2777701055 @default.
• W1841011077 hasConcept C2778227246 @default.
• W1841011077 hasConcept C2780235182 @default.
• W1841011077 hasConcept C502942594 @default.
• W1841011077 hasConcept C553184892 @default.
• W1841011077 hasConcept C55493867 @default.
• W1841011077 hasConcept C71924100 @default.
• W1841011077 hasConcept C86803240 @default.
• W1841011077 hasConcept C8891405 @default.
• W1841011077 hasConcept C90375314 @default.
• W1841011077 hasConceptScore W1841011077C104317684 @default.
• W1841011077 hasConceptScore W1841011077C142724271 @default.
• W1841011077 hasConceptScore W1841011077C147483822 @default.
• W1841011077 hasConceptScore W1841011077C150194340 @default.
• W1841011077 hasConceptScore W1841011077C154317977 @default.
• W1841011077 hasConceptScore W1841011077C167672396 @default.
• W1841011077 hasConceptScore W1841011077C190727270 @default.
• W1841011077 hasConceptScore W1841011077C202751555 @default.
• W1841011077 hasConceptScore W1841011077C203014093 @default.
• W1841011077 hasConceptScore W1841011077C2776090121 @default.

• next